Loading patent…
AssigneeSushma Paul Berlia
InventorsSushma Paul Berlia, Nishant Berlia, Anupama Diwan, Sunder Singh Bhandari
Estimating the term…
The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free.
A controlled release oral formulation comprising about 400 to about 800 mg of flavoxate salt as an active ingredient and further comprising polyvinylpyrrolidone K30 (PVP K30) and/or colloidal silicon dioxide;
A formulation comprising about 400 mg to about 800 mg flavoxate salt as an active ingredient, HPMC K4M, and HPMC K15M, wherein the formulation further comprises PVP K30 and/or colloidal silicon dioxide and does not comprise an acidifying agent.
Dependencies are inferred from the claim text.